- Home
- HIFS vs MNMD Comparison
HIFS vs MNMD Comparison
Compare HIFS & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIFS
- MNMD
- Stock Information
- Founded
- HIFS 1834
- MNMD 2019
- Country
- HIFS United States
- MNMD United States
- Employees
- HIFS N/A
- MNMD N/A
- Industry
- HIFS Major Banks
- MNMD Pharmaceuticals and Biotechnology
- Sector
- HIFS Finance
- MNMD Health Care
- Exchange
- HIFS Nasdaq
- MNMD Nasdaq
- Market Cap
- HIFS 611.4M
- MNMD 709.9M
- IPO Year
- HIFS N/A
- MNMD N/A
- Fundamental
- Price
- HIFS $280.51
- MNMD $9.55
- Analyst Decision
- HIFS
- MNMD Strong Buy
- Analyst Count
- HIFS 0
- MNMD 7
- Target Price
- HIFS N/A
- MNMD $24.71
- AVG Volume (30 Days)
- HIFS 39.8K
- MNMD 1.1M
- Earning Date
- HIFS 10-10-2025
- MNMD 11-06-2025
- Dividend Yield
- HIFS 0.90%
- MNMD N/A
- EPS Growth
- HIFS 63.41
- MNMD N/A
- EPS
- HIFS 15.35
- MNMD N/A
- Revenue
- HIFS $75,066,000.00
- MNMD N/A
- Revenue This Year
- HIFS N/A
- MNMD N/A
- Revenue Next Year
- HIFS N/A
- MNMD N/A
- P/E Ratio
- HIFS $17.89
- MNMD N/A
- Revenue Growth
- HIFS 37.00
- MNMD N/A
- 52 Week Low
- HIFS $209.71
- MNMD $4.70
- 52 Week High
- HIFS $300.00
- MNMD $11.02
- Technical
- Relative Strength Index (RSI)
- HIFS 57.07
- MNMD 53.35
- Support Level
- HIFS $271.20
- MNMD $8.70
- Resistance Level
- HIFS $284.03
- MNMD $9.95
- Average True Range (ATR)
- HIFS 9.62
- MNMD 0.55
- MACD
- HIFS -0.48
- MNMD -0.02
- Stochastic Oscillator
- HIFS 45.62
- MNMD 40.95
About HIFS Hingham Institution for Savings
Hingham Institution for Savings is a savings bank based in Hingham, Massachusetts, and is involved in the business of residential and commercial real estate mortgage lending and also financial and banking services. The bank's financial services include personal checking accounts, personal mortgages, home equity lines of credit, money market accounts, savings accounts, certificates of deposit, and business checking accounts. Its lending portfolio mainly encompasses commercial real estate, residential owner-occupied real estate, and loans for the construction of residential real estate.
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).